| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
PI3Kγ
The primary target of OMS14 is phosphoinositide 3-kinase (PI3K), a key enzyme in the PI3K/AKT/mTOR signaling pathway that is frequently hyperactivated in cancer. Specifically, OMS14 inhibits the PI3Kgamma isoform (19% inhibition at 100 uM) and the PIK3CD/PIK3R1 (p110delta/p85alpha) complex (65% inhibition at 100 microM). The inhibition of the p110delta isoform is likely the primary driver of its anticancer effects. |
|---|---|
| ln Vitro |
OMS14 (0-100 μM) inhibits the proliferation of A549 and MCF-7 cells with IC50 values of 22.13 and 26.09 μM, respectively[1]. OMS14 (100 μg/mL) inhibits the formation of Staphylococcus aureus colonies with a diameter of 15 mm[1].
In vitro, OMS14 effectively inhibits the proliferation of various human cancer cell lines. It showed potent activity against lung cancer (A549) and breast cancer (MCF-7) cells, with IC50 values of 22.13 microM and 26.09 microM, respectively. It was identified as one of the most potent compounds in its chemical series, with IC50 values ranging from 22.13 to 61.03 microM across different cell lines. The anticancer effects were demonstrated to be likely related to the inhibition of PI3K signaling. |
| ln Vivo |
The search results did not contain any specific in vivo activity data for OMS14. While the compound shows promising in vitro anticancer activity against lung and breast cancer cell lines, no studies have been published that describe its efficacy in animal models. Future studies would likely involve evaluating its antitumor efficacy in mouse xenograft models of lung or breast cancer. OMS14 also shows potential as an antibacterial agent, inhibiting Staphylococcus aureus colony formation at a concentration of 100 microg/mL.
|
| Enzyme Assay |
The in vitro PI3K enzyme inhibition assay is performed using recombinant human PI3K isoforms (alpha, beta, gamma, delta). The enzyme is incubated in a reaction buffer containing phosphatidylinositol (4,5)-bisphosphate (PIP2) and ATP. OMS14 is added at concentrations ranging from 0.1 to 1000 uM. Following the reaction, the amount of phosphatidylinositol (3,4,5)-trisphosphate (PIP3) produced is detected using a homogeneous time-resolved fluorescence (HTRF) or AlphaScreen assay. The IC50 is calculated from the dose-response curve. OMS14 is a weak PI3K inhibitor, showing 19% inhibition of PI3Kgamma at 100 microM.
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: A549 and MCF-7 Tested Tested Concentrations: 0-100 μM Incubation Duration: 72 h Experimental Results: Inhibited cell proliferations. For cell-based studies, A549 (lung cancer) and MCF-7 (breast cancer) cells are seeded in 96-well plates at a density of 5,000-10,000 cells per well in DMEM with 10% FBS. After 24 hours, the medium is replaced with fresh medium containing varying concentrations of OMS14 (0-100 uM). After 48-72 hours of incubation, cell viability is measured using an MTT or CellTiter-Glo assay. The IC50 values (22.13 microM for A549 cells and 26.09 microM for MCF-7 cells) are calculated from the dose-response curves. All experiments are typically performed in triplicate. |
| Animal Protocol |
A standard protocol for evaluating a new anticancer agent in vivo would involve a xenograft model. Female BALB/c nude mice (6-8 weeks old) would be subcutaneously injected with 5×10⁶ A549 or MCF-7 cells in 0.1 mL of PBS/Matrigel (1:1). Once tumors reach an average volume of approximately 100-150 mm3, the mice would be randomized into treatment groups (n=6-8 per group). OMS14 would be formulated in a suitable vehicle (e.g., 10% DMSO, 40% PEG300, 5% Tween 80, 45% saline) and administered intraperitoneally (IP) or orally (PO) at doses of 10-100 mg/kg. Tumor volume would be measured every 2-3 days with calipers, and body weight would be monitored as an indicator of toxicity.
|
| ADME/Pharmacokinetics |
Specific PK data for OMS14 was not available in the search results. The compound is a small molecule (MW ~450-500) with a predicted moderate LogP, suggesting it may have good cell permeability. For in vivo studies, the compound can be formulated in 10% DMSO, 40% PEG300, 5% Tween 80, and 45% saline for intraperitoneal injection. For oral dosing, it could be suspended in 0.5% methylcellulose. No specific half-life (t½) or bioavailability data were found.
|
| Toxicity/Toxicokinetics |
No specific toxicological data for OMS14 was available in the search results. In vitro cytotoxicity data indicates that OMS14 has moderate cytotoxicity against cancer cells, with IC50 values in the low micromolar range (22-61 uM). As a research chemical, standard safety precautions should be followed, including the use of personal protective equipment (PPE) when handling. The compound should be stored at -20degC, as indicated in the product specifications.
|
| References | |
| Additional Infomation |
OMS14 is a research-grade chemical probe used to study the effects of PI3Kdelta/gamma inhibition in cancer and immune-related disorders. The compound was part of a study that identified 2-aminobenzothiazole derivatives as potential anticancer agents. Its development highlights the ongoing search for novel PI3K inhibitors with new chemical scaffolds. It is not an FDA-approved drug and is for research use only.
|
| Molecular Formula |
C21H22N6O4S
|
|---|---|
| Molecular Weight |
454.50
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~220.02 mM; with ultrasonication (<60°C))
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (11.00 mM)(saturation unknown) in 10% DMSO 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one),clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution and add it to 900 μL corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2002 mL | 11.0011 mL | 22.0022 mL | |
| 5 mM | 0.4400 mL | 2.2002 mL | 4.4004 mL | |
| 10 mM | 0.2200 mL | 1.1001 mL | 2.2002 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
